Hwang, Inhwan
Kim, Jeong Eun
Jeong, Jae Ho
Ahn, Jin-Hee
Jung, Kyung Hae
Son, Byung Ho
Kim, Hak Hee
Shin, Junyoung
Lee, Hee Jin
Gong, Gyungyub
Kim, Sung-Bae http://orcid.org/0000-0001-5588-8332
Clinical trials referenced in this document:
Documents that mention this clinical trial
Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
https://doi.org/10.1007/s10549-023-06971-7
Funding for this research was provided by:
Sanofi-Aventis (Grant No.2012-0116)
Article History
Received: 22 March 2023
Accepted: 3 May 2023
First Online: 26 June 2023
Declarations
:
: HJL is founder of Neogene TC. KHJ has advisory roles at Astra-Zeneca, BIXINK, MSD, Novartis, Pfizer, Roche, Takeda and Everest Medicine. SBK is a consultant on the advisory boards of Novartis, AstraZeneca, Lilly, Dae Hwa Pharmaceutical Co. Ltd, ISU Abxis, and Daiichi-Sankyo, and has received research funding from Novartis, Sanofi-Aventis, and DongKook Pharm Co., and owns stock in Genopeaks and NeogeneTC. No other authors have any conflicts of interest to declare in relation to this study.
: The Institutional Review Board (IRB) at our institution approved this study. All procedures involving human participants followed the ethical standards of the institutional and/or national research committee, and of the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: All of the enrolled human subjects in this study provided written informed consent to participate and to the publication of the findings.
: Informed consent was obtained from all individual participants included in the study.
: The authors confirm that this manuscript does not contains any identifying personal information regarding the study participants.